CGVHD HEALTHCARE PATHWAY, UNMET NEED AND ECONOMIC BURDEN IN ALGERIA: A FIRST PHARMACOECONOMIC STUDY
Author(s)
Aissa A. Benbachir, Dr1, Yasmine Zineb Hatem, Dr1, Abdelhakim Boudis, Pr2, zakia hachelaf, MBA, MSc3, Malek Benakli, Pr1.
1Youssef Al-Khatib University of Health Sciences, Algiers, Algeria, Algiers, Algeria, 2Algerian Federation of Pharmacy, Algiers, Algeria, 3Sanofi, algiers, Algeria.
1Youssef Al-Khatib University of Health Sciences, Algiers, Algeria, Algiers, Algeria, 2Algerian Federation of Pharmacy, Algiers, Algeria, 3Sanofi, algiers, Algeria.
OBJECTIVES: Chronic graft-versus-host disease (cGVHD) is a major complication of allogeneic hematopoietic stem cell transplantation, associated with long-term morbidity, reduced quality of life, and substantial healthcare use. This study aimed to describe the care pathway and estimate the economic burden of cGVHD in Algeria. It is the first pharmacoeconomic study on cGVHD in Algeria.
METHODS: A retrospective monocentric study was conducted in 2025 in the hematology department of the Pierre and Marie Curie Center, Algiers. It included 80 patients diagnosed with cGVHD according to NIH and national criteria. Data were collected from treating hematologists, hospital records, and pharmaceutical databases. Costs were estimated from hospital and societal perspectives, and a deterministic one-way sensitivity analysis was performed on the main cost components.
RESULTS: Management was complex and involved repeated hospitalizations, specialist consultations, complementary tests, supportive care, and prolonged systemic treatment. The mean annual direct medical cost was 1 660 635,11 DZD per patient. Drug costs were the largest component at 528,635 DZD, followed by supportive care (465,400 DZD), hospitalizations (420,000 DZD), complementary tests (191,800 DZD), and specialist consultations (54,800 DZD). The minimal annual cost reached 2 041 457,11 DZD (13443,34€) per patient when personal expenses and indirect costs were included. These comprised 253,332 DZD in out-of-pocket expenses and 127,490 DZD in productivity loss due to prolonged work absenteeism. The sensitivity analysis confirmed our findings, and showed that drug costs were the primary cost driver followed by supportive care.
CONCLUSIONS: cGVHD represents a substantial burden with annual costs exceeding 2 million DZD per patient. Improved access to innovative therapies and enhanced multidisciplinary coordination are needed to optimize patient outcomes and reduce healthcare expenditure
METHODS: A retrospective monocentric study was conducted in 2025 in the hematology department of the Pierre and Marie Curie Center, Algiers. It included 80 patients diagnosed with cGVHD according to NIH and national criteria. Data were collected from treating hematologists, hospital records, and pharmaceutical databases. Costs were estimated from hospital and societal perspectives, and a deterministic one-way sensitivity analysis was performed on the main cost components.
RESULTS: Management was complex and involved repeated hospitalizations, specialist consultations, complementary tests, supportive care, and prolonged systemic treatment. The mean annual direct medical cost was 1 660 635,11 DZD per patient. Drug costs were the largest component at 528,635 DZD, followed by supportive care (465,400 DZD), hospitalizations (420,000 DZD), complementary tests (191,800 DZD), and specialist consultations (54,800 DZD). The minimal annual cost reached 2 041 457,11 DZD (13443,34€) per patient when personal expenses and indirect costs were included. These comprised 253,332 DZD in out-of-pocket expenses and 127,490 DZD in productivity loss due to prolonged work absenteeism. The sensitivity analysis confirmed our findings, and showed that drug costs were the primary cost driver followed by supportive care.
CONCLUSIONS: cGVHD represents a substantial burden with annual costs exceeding 2 million DZD per patient. Improved access to innovative therapies and enhanced multidisciplinary coordination are needed to optimize patient outcomes and reduce healthcare expenditure
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE583
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)